BioAtla, Inc. Common Stock
Symbol: BCAB (NASDAQ)
0.64
▼ (-2.94%) -0.019
Company Description:
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Key Stats
- Today's Open: $0.674
- Today's High: $0.68
- Today's Low: $0.633
- Today's Volume: 10.75K
- Yesterday Close: $0.6563
- Yesterday High: $0.7151
- Yesterday Low: $0.6303
- Yesterday Volume: 898.81K
- Last Min Volume: 1
- Last Min High: $0.637
- Last Min Low: $0.637
- Last Min VWAP: $0.637
Company Profile
- Name: BioAtla, Inc. Common Stock
- Website: https://www.bioatla.com
- Listed Date: 2020-12-16
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001826892
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $40.52M
- Round Lot: 100
- Outstanding Shares: 58.72M
- Asset Type: CS
RECENT FILINGS FOR BCAB
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-15 | SCHEDULE 13G | View |
| 2025-09-22 | 8-K | View |
| 2025-09-02 | 4 | View |
| 2025-09-02 | 4 | View |
| 2025-09-02 | 4 | View |
| 2025-09-02 | 4 | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-06-20 | 8-K | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-06-03 | 4 | View |
| 2025-05-20 | SCHEDULE 13G/A | View |
Latest News on BCAB